Market
Which country will first approve Flash Radiotherapy for clinical use by the end of 2026?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Government health department announcements or regulatory agency approvals
Story
New Ultra-Fast Cancer Treatment ErSO-TFPy Promises Less Side Effects and Rapid Results in Less Than a Second
Jan 23, 2025, 03:02 AM
Recent research highlights a groundbreaking ultra-fast cancer treatment that could potentially replace conventional radiotherapy. This innovative approach, referred to as Flash Radiotherapy, promises to address a broader range of cancers while minimizing side effects and significantly reducing treatment time to less than a second. Additionally, a study on the drug candidate ErSO-TFPy has demonstrated its effectiveness in eradicating small breast cancer tumors in mice, indicating potential for treating estrogen receptor-positive breast cancer with minimal side effects. Further testing is required to confirm these findings and assess the treatments' applicability in clinical settings.
View original story
Similar markets
United States • 25%
China • 25%
European Union • 25%
Other • 25%
Other • 25%
Brazil • 25%
India • 25%
China • 25%
China • 25%
United States • 25%
Other • 25%
European Union • 25%
United States • 25%
Germany • 25%
Other • 25%
United Kingdom • 25%
USA • 25%
EU • 25%
China • 25%
Other • 25%
United States • 25%
Other • 25%
European Union • 25%
Japan • 25%
China • 25%
Other • 25%
Russia • 25%
USA • 25%
United Kingdom • 25%
Other • 25%
United States • 25%
Germany • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
United States • 25%
Germany • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
European Union • 25%
China • 25%
United States • 25%
Other • 25%
China • 25%
United States • 25%
European Union • 25%
Other • 25%